Abstract
Our previous work showed that arsenic trioxide down-regulated Cx43 and attenuated the angiogenic potential of human late endothelial progenitor cells (EPC). However, the relation between Cx43 and angiogenic activity of the EPC remained unclear. In the study, human late EPC were treated with siRNA specific to Cx43 (Cx43siRNA). The expression profiles as well as activity of the treated cells were examined. In parallel, the angiogenic potential of human EPC treated with Cx43siRNA was evaluated using murine hind limb ischemic model. The results showed that, in the EPC treated with Cx43siRNA, the activity of migration, proliferation, and angiogenic potential were attenuated, accompanied by reduction in vascular endothelial growth factor (VEGF) expression. In hind limb ischemia mice, EPC treated with Cx43siRNA lost the therapeutic angiogenic potential. VEGF supplementation partially recovered the activity impaired by Cx43 down-regulation. In conclusion, reduced Cx43 expression per se in the EPC causes decreased expression of VEGF and impaired angiogenic potential of the cells. Prevention of Cx43 reduction is a potential target to maintain the angiogenic potential of the EPC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tanaka K, Sata M (2007) Therapeutic application of bone marrow-derived progenitor cells for vascular diseases: magic bullets having the good without the bad? Int J Gerontol 1:10–21
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967
Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221–228
Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95:343–353
Pathak AP, Hochfeld WE, Goodman SL, Pepper MS (2008) Circulating and imaging markers for angiogenesis. Angiogenesis 11:321–335
Bengel FM, Schachinger V, Dimmeler S (2005) Cell-based therapies and imaging in cardiology. Eur J Nucl Med Mol Imaging 32(Suppl 2):S404–S416
Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, Bunting S, Steinmetz HG, Gurtner GC (2004) Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 164:1935–1947
Dobaczewski M, Bujak M, Zymek P, Ren G, Entman ML, Frangogiannis NG (2006) Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res 324:475–488
Chou Y, Tsai CH, Ueng KC, Tian TY, Chen SC, Yeh HI (2007) Endothelial gap junctions are down-regulated by arsenic trioxide. Eur J Pharmacol 569:29–36
Bunderson M, Coffin JD, Beall HD (2002) Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol Appl Pharmacol 184:11–18
Kumagai Y, Pi J (2004) Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction. Toxicol Appl Pharmacol 198:450–457
Xiao YF, Liu SX, Wu DD, Chen X, Ren LF (2006) Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J Gastroenterol 12:5780–5786
Li JY, Su CH, Wu YJ, Tien TY, Hsieh CL, Chen CH, Tseng YM, Shi GY, Wu HL, Tsai CH, Lin FY, Yeh HI (2011) Therapeutic angiogenesis of human early endothelial progenitor cells is enhanced by thrombomodulin. Arterioscler Thromb Vasc Biol 31:2518–2525
Wang HH, Lin CA, Lee CH, Lin YC, Tseng YM, Hsieh CL, Chen CH, Tsai CH, Hsieh CT, Shen JL, Chan WH, Chang WH, Yeh HI (2011) Fluorescent gold nanoclusters as a biocompatible marker for in vitro and in vivo tracking of endothelial cells. ACS Nano 5:4337–4344
Wang HH, Kung CI, Tseng YY, Lin YC, Chen CH, Tsai CH, Yeh HI (2008) Activation of endothelial cells to pathological status by down-regulation of connexin43. Cardiovasc Res 79:509–518
Yeh HI, Lee PY, Su CH, Tian TY, Ko YS, Tsai CH (2006) Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens 19:129–135
Yeh HI, Lai YJ, Chang HM, Ko YS, Severs NJ, Tsai CH (2000) Multiple connexin expression in regenerating arterial endothelial gap junctions. Arterioscler Thromb Vasc Biol 20:1753–1762
Acknowledgments
We gratefully acknowledge the supports of research grants from Taiwan (R.O.C.): National Science Council (NSC 99-2314-B-195-009-MY2) and Mackay Memorial Hospital (MMH-E-99003, 100-03).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wang, HH., Su, CH., Wu, YJ. et al. Reduction of connexin43 in human endothelial progenitor cells impairs the angiogenic potential. Angiogenesis 16, 553–560 (2013). https://doi.org/10.1007/s10456-013-9335-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10456-013-9335-z